Multicenter phase II trial of etoposide in refractory small cell lung cancer

B. F. Issell, L. H. Einhorn, R. L. Comis, R. D. Lawson, L. H. Baker, H. A. Harvey, V. A. Lanzotti, G. L. Wampler, J. R. Daniels, P. N. Anderson

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

Original languageEnglish (US)
Pages (from-to)127-128
Number of pages2
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - Jul 31 1985

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Issell, B. F., Einhorn, L. H., Comis, R. L., Lawson, R. D., Baker, L. H., Harvey, H. A., Lanzotti, V. A., Wampler, G. L., Daniels, J. R., & Anderson, P. N. (1985). Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treatment Reports, 69(1), 127-128.